Home > Boards > US OTC > Medical - Healthcare > BioRestorative Therapies Inc. (BRTX)

BRTX News**$6,121,000 Financing & Emerged from BK

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
stervc Member Profile
Member Level 
Followed By 4,434
Posts 21,887
Boards Moderated 19
Alias Born 09/20/00
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/24/2020 4:31:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/24/2020 4:14:50 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/20/2020 4:49:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/20/2020 4:05:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/5/2020 4:26:46 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/26/2020 4:20:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/20/2020 4:36:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/14/2020 5:48:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/11/2020 5:31:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/7/2020 4:40:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/31/2020 5:23:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/24/2020 4:55:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/16/2020 4:38:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/10/2020 5:07:35 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 1/9/2020 6:01:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/7/2020 5:19:47 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/27/2019 6:05:49 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/26/2019 4:42:33 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 12/23/2019 5:00:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/18/2019 5:17:00 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 12/13/2019 5:33:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2019 5:31:06 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 12/10/2019 5:27:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/6/2019 4:33:50 PM
stervc Member Level  Friday, 11/20/20 07:49:35 AM
Re: BCNstocks post# 52178
Post # of 53256 
BRTX News**$6,121,000 Financing & Emerged from BK

This is great news for BRTX as it has emerged from Bankruptcy (BK) while already received $3,848,000 in financing and can get up to another $3,500,000 minus $1,227,000 for BK expenses for a total of $6,121,000 in financing.
($3,500,000 - $1,227,000 = $2,273,000 then... $2,273,000 + $3,848,000 = $6,121,000)

To add.. all of the requirements have been met to emerge... all creditor claims have been fully satisfied... and the BRTX equity holders (common shares) have retained their shares... BRTX was also able to preserve all of their intellectual property assets as they look forward to initiating their Phase 2 clinical trial... and as we all now know... from the company’s emergence from Chapter 11 reorganization, FINRA has removed the “Q” at the end of its trading symbol:
Quote:

http://www.globenewswire.com/news-release/2020/11/20/2130866/0/en/BioRestorative-Therapies-Emerges-from-Chapter-11-Reorganization.html
BioRestorative Therapies Emerges from Chapter 11 Reorganization

MELVILLE, N.Y., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that its amended joint plan of reorganization has become effective and it has emerged from Chapter 11 reorganization. Pursuant to the confirmed plan of reorganization, the Company has received $3,848,000 in financing. The confirmed plan of reorganization also provides for additional funding, subject to certain conditions, of $3,500,000 less the sum of the debtor-in-possession financing provided to the Company during the reorganization (approximately $1,227,000) and the costs incurred by the debtor-in-possession lender.

In connection with the reorganization, Lance Alstodt has been appointed the Company’s President, Chief Executive Officer and Chairman of the Board. Mr. Alstodt said, “This process has been a long and challenging journey for the Company. I’m inspired by the great resolve and execution from our employees, professionals and investors. We are very pleased that all requirements have been met for us to emerge. Allowed creditor claims have been fully satisfied and, as importantly, our equity holders have retained their shares in this exciting new opportunity. We were able to preserve all of our intellectual property assets and look forward to initiating our Phase 2 clinical trial.”

Based upon the Company’s emergence from Chapter 11 reorganization, FINRA has removed the “Q” at the end of its trading symbol. Shareholders do not need to exchange their shares for new shares.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

• Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:
Email: ir@biorestorative.com



v/r
Sterling


Exit Strategy & Etiquette Thoughts for a Stock
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128822531
I never give investing advice; only my beliefs for risks in a stock.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences